Hemolytic Indicators, Special Stains, Other Studies, and Flow Cytometry

Accelerated red-cell destruction, whether by intravascular fragmentation or extravascular macrophage-mediated clearance, produces two laboratory groups that move in opposite directions: evidence of increased hemoglobin catabolism and evidence of compensatory erythropoiesis. Reading the two groups together localizes the process, dates it, and separates hemolysis from bleeding, another major cause of red-cell loss.

Evidence of increased hemoglobin catabolism

• Bilirubin. Unconjugated (indirect) bilirubin rises, sometimes visibly as icteric plasma; with normal liver function the direct (conjugated) fraction stays normal. Unconjugated bilirubin travels bound to albumin, so the glomerulus never filters it and it stays out of the urine even in marked hemolysis; urine urobilinogen, from gut-flora reduction of conjugated bilirubin, may rise instead.
• Plasma and urine hemoglobin, urine hemosiderin. Free hemoglobin, methemoglobin, and hemopexin-heme give plasma a coffee-brown color and urine a root-beer color once the binding capacity of haptoglobin and hemopexin is exceeded. Plasma stays visually clear until free hemoglobin reaches roughly 50 mg/dL, while clinically relevant hemolysis can run as low as 15 mg/dL, so a urine dipstick positive for blood with few or no intact erythrocytes in the sediment points to pigmenturia from hemoglobin or myoglobin. Renal tubular cells that reabsorb filtered heme and later slough into the urine stain with Prussian blue; this hemosiderinuria marks hemolysis over the preceding days.
• Haptoglobin. Plasma haptoglobin binds free hemoglobin and the complex clears. A markedly decreased haptoglobin supports an intravascular hemolytic component; it may remain normal in purely extravascular hemolysis and must be read alongside liver function and its acute-phase response.
• Lactate dehydrogenase. Ruptured erythrocytes release lactate dehydrogenase, which is nonspecific and also rises in myocardial infarction and liver disease. Within a consistent hemolysis picture, an elevated LDH supports the hemolytic process itself and needs no organ-injury explanation.

Evidence of increased erythropoiesis

• Reticulocyte count, absolute count, and production index. The reticulocyte count is a sensitive, commonly used indicator. It is expected to rise within days when the marrow is healthy and iron, vitamin B12, and folate are replete. In an anemic patient, an elevated reticulocyte count with hemorrhage excluded should trigger a hemolysis workup. Two exceptions blunt the expected response: an aplastic crisis superimposed on chronic hemolysis, and an autoimmune process that also targets marrow erythroid precursors.
• Complete count and film. The film shows polychromasia and nucleated red cells. A rising MCV reflects the influx of larger shift reticulocytes; compare it with the patient’s own baseline because the MCV may still fall within the population interval. A rising RDW reflects the added variance from larger cells. Reactive leukocytosis and thrombocytosis are possible. Spherocytes occur with macrophage-mediated hemolysis, and schistocytes occur with fragmentation hemolysis. Schistocytes alongside a falling platelet count raise concern for a platelet-consuming microangiopathic process such as DIC.
• Bone marrow, rarely needed, shows erythroid hyperplasia with a decreased myeloid-to-erythroid ratio; core biopsy assesses cellularity more accurately than an aspirate.

Additional workup follows the pattern: urinalysis for hemoglobinuria, urobilinogen, and hemosiderin and stool studies broaden the differential; the direct antiglobulin test separates immune from non-immune hemolysis; and once the reticulocyte count, MCV, and film classify the anemia, iron studies or vitamin B12 and folate assays direct further testing.

Special stains

Cytochemical stains exploit lineage-restricted enzyme activity to classify blasts when routine morphology is ambiguous. Only blast positivity carries diagnostic weight; staining in maturing granulocytes is normal.

• Myeloperoxidase (MPO) lives in primary granules from the promyelocyte stage onward in neutrophils, eosinophils, and weakly in monocytes; lymphocytes are negative, and Auer rods stain strongly.¹
• Sudan black B (SBB) stains cellular lipid and closely parallels the MPO pattern, potentially more sensitive in early myeloid cells: granulocytes stain with increasing intensity as they mature, monocytes range negative to weak, and lymphoid cells are negative.
• Esterases separate granulocytic from monocytic lineage. Naphthol AS-D chloroacetate esterase, the specific esterase, is positive in granulocytic cells including Auer rods and negative to weak in monocytic cells. α-Naphthyl acetate and α-naphthyl butyrate esterases, the nonspecific esterases, show strong diffuse positivity in monocytic cells, confirmed by inhibition with added sodium fluoride; granulocytic and lymphoid cells are generally negative, with occasional dot positivity in lymphocytes.

• Prussian blue (Perls) iron stain grades marrow storage iron on the aspirate smear and identifies ring sideroblasts, erythroid precursors carrying a perinuclear collar of iron granules in reactive and neoplastic sideroblastic states. The aspirate is preferred over a decalcified core-biopsy section, because decalcification leaches iron and can falsely suggest depleted stores.
• Kleihauer-Betke acid elution exploits the resistance of Hb F to acid elution: ethanol-fixed films are exposed to citrate-acid buffer, which strips adult hemoglobin from erythrocytes and leaves hemoglobin-depleted ghost cells, while Hb F-containing cells stay intact and stainable. The test distinguishes pancellular from heterocellular Hb F distribution, which separates hereditary persistence of fetal hemoglobin from thalassemia, and quantifies fetal-maternal hemorrhage to guide Rh immune globulin dosing; those transfusion-medicine applications are covered with hemolytic disease of the fetus and newborn.¹

Erythrocyte sedimentation rate

Erythrocytes carry a net negative surface charge and normally repel one another. Elevated fibrinogen and immunoglobulins reduce that zeta potential and promote rouleaux, which increases the effective settling mass. The ESR is the distance in millimeters that erythrocytes in anticoagulated blood fall in 1 hour standing undisturbed. It rises with anemia itself, independent of inflammation, and with plasma protein or viscosity changes. Because it is nonspecific, clinicians use it to monitor a known inflammatory condition; it is a poor screening test in asymptomatic people, and C-reactive protein is often the more reliable monitoring alternative.

Modified Westergren method, the ICSH reference approach with modified and alternate methods addressed by ICSH 2017 guidance and CLSI H02-A5 remaining technically valid: blood is diluted 4:1 with 3.8% sodium citrate, or collected into dedicated sedimentation tubes (an ordinary 9:1 coagulation citrate tube carries the wrong ratio and is not acceptable), loaded into a 200-mm column, and read after 60 minutes standing perfectly level at 18 to 25 °C, from the bottom of the plasma meniscus to the top of the sedimented cells, excluding the buffy coat.² The Wintrobe method uses a shorter 100-mm tube and undiluted blood, adding some sensitivity to mildly elevated rates at the cost of range before the column fully sediments.

Sources of error. Excess anticoagulant spheres the cells and blunts rouleaux, falsely lowering the result; oxalate or heparin shrink cells and raise it. Specimens are tested within 4 hours at room temperature, or refrigerated up to 24 hours and rewarmed for at least 15 minutes, because standing longer degrades rouleaux-forming capacity. Even a slight tube tilt accelerates settling and falsely raises the result, and in severe anemia the ESR becomes so nonspecifically elevated that it loses diagnostic value.

G6PD deficiency testing

Glucose-6-phosphate dehydrogenase catalyzes the first, rate-limiting step of the hexose monophosphate shunt, oxidizing glucose-6-phosphate to 6-phosphoglucono-δ-lactone while reducing NADP⁺ to NADPH. Glutathione reductase then spends that NADPH regenerating reduced glutathione, the erythrocyte’s primary defense against oxidant damage to hemoglobin, membrane lipids, and enzymes. In the unstressed cell only 5 to 10% of glucose flux crosses this shunt, but flux rises up to thirtyfold under oxidant challenge, and G6PD-deficient cells forfeit exactly that reserve, leaving them exposed to oxidant-triggered hemolysis from drugs, infection, or fava beans.³

• Quantitative spectrophotometric assay. The reference method measures the rate of NADPH generation from a hemolysate with substrate and cofactor, read as rising absorbance at 340 nm. It quantifies enzyme activity for diagnosis and severity assessment.⁴
• Qualitative screening tests run the same reaction to a visual or fluorometric endpoint. The fluorescent-spot test uses NADPH’s fluorescence against nonfluorescent NADP; dye-reduction lateral-flow devices rely on NADPH reducing a tetrazolium dye to a visible product. These screens reliably identify hemizygous males and severely deficient homozygous or compound-heterozygous females with activity below about 20%, but they miss mild-to-moderate deficiency and most heterozygous females, so any deficient or borderline screen reflexes to the quantitative assay.
• Timing limitation. Reticulocytes carry higher G6PD activity than mature erythrocytes, and acute hemolysis provokes reticulocytosis, so testing during or immediately after an episode can return a falsely normal or falsely elevated activity. Retest 2 to 3 months after the episode whenever the clinical course allows, and suspect G6PD deficiency whenever reticulocytosis accompanies an unexpectedly normal activity level.
• Molecular testing targets known point mutations; the great majority of G6PD variants are single-nucleotide substitutions. It supports heterozygous female carrier detection because a mosaic mixture of normal and deficient cells often gives an indeterminate phenotypic result. It also applies to recently transfused patients and patients in an acute episode because molecular results are unaffected by reticulocytosis. Routine leukoreduced transfusion rarely contaminates the result, but the transfusion history goes to the testing laboratory because residual donor leukocytes can occasionally contribute DNA.

Flow cytometry immunophenotyping

Flow cytometry types individual cells in suspension by measuring light scatter and the binding of fluorochrome-conjugated monoclonal antibodies to surface and cytoplasmic antigens. A hydrodynamically focused single-cell stream crosses a laser: forward scatter approximates size, side scatter approximates internal complexity or granularity, and each fluorescence channel reports antigen density for one conjugated antibody. Multicolor panels combine several markers per cell and resolve populations that overlap on any single parameter, a necessity because normal hematopoietic maturation is continuous. Neoplastic cells characteristically show maturation arrest plus aberrant, asynchronous marker combinations absent from normal maturation.

Workflow. Transport and stability limits are specimen- and method-specific: cerebrospinal fluid and other fragile fluids process immediately unless placed in a laboratory-validated stabilizing medium. Red cells are lysed to isolate the nucleated population, and viability is checked, commonly with propidium iodide. The antibody panel follows, with fixation and permeabilization added when a target antigen is intracellular. Data are collected ungated, recording every event, so internal positive and negative controls survive and unexpected populations stay visible; gating is an analysis step, most often beginning from the CD45-antigen versus side-scatter plot, where lymphocytes, monocytes, mature granulocytes, and blasts each occupy a characteristic region.

Lineage-defining markers:

CD45 density itself is informative: lymphocytes stain brightest, monocytes and mature granulocytes intermediate to bright, and blasts and erythroid precursors characteristically dim to negative, the basis of the standard screening plot.

Immunophenotypes of major hematologic neoplasms:

Other clinical applications.

• Lymphocyte subset enumeration reports the CD4 count and CD4:CD8 ratio as an absolute count (cells/µL) and a relative percentage; Immunology owns the HIV staging and monitoring context that consumes those values.
• Paroxysmal nocturnal hemoglobinuria is diagnosed by flow cytometry; the older Ham and sucrose hemolysis tests are less sensitive. PNH clones show decreased-to-absent expression of glycosylphosphatidylinositol-anchored proteins (CD55 and CD59 on erythrocytes; CD24 and FLAER on granulocytes), because the underlying stem-cell mutation disrupts GPI-anchor synthesis. Distinct CD59-negative (type III), partially deficient (type II), and normal (type I) erythrocyte populations may coexist.
• Primary and secondary immunodeficiency evaluation includes testing for absent CD11/CD18 in leukocyte adhesion deficiency and oxidative-burst assays in chronic granulomatous disease.